S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$224.45
+2.99 (+1.35%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$218.10
$224.80
50-Day Range
$205.07
$236.53
52-Week Range
$189.40
$262.38
Volume
491,073 shs
Average Volume
692,391 shs
Market Capitalization
$32.97 billion
P/E Ratio
40.74
Dividend Yield
0.78%
Price Target
$263.17

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
17.2% Upside
$263.17 Price Target
Short Interest
Healthy
0.59% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
-0.15mentions of ResMed in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth
12.70%
From $6.38 to $7.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

59th out of 1,029 stocks

Surgical & Medical Instruments Industry

5th out of 105 stocks

RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

Contrasting Vivos (OTCMKTS:RDGL) and ResMed (NYSE:RMD)
ResMed Inc. (RMD) To Go Ex-Dividend on February 8th
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Karen Drexler Sells 594 Shares of ResMed Inc. (NYSE:RMD) Stock
ResMed (NYSE:RMD) Rating Reiterated by William Blair
ResMed (NYSE:RMD) PT Raised to $260.00
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Ex-Dividend for 12/15 Dividend
11/09/2022
Dividend Payable
12/15/2022
Last Earnings
1/26/2023
Today
2/07/2023
Ex-Dividend for 3/16 Dividend
2/08/2023
Dividend Payable
3/16/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
8,160
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$263.17
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+17.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$779.44 million
Pretax Margin
26.57%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$7.14 per share
Book Value
$22.97 per share

Miscellaneous

Free Float
144,867,000
Market Cap
$32.97 billion
Optionable
Optionable
Beta
0.47

Social Links


Key Executives

  • Mick Farrell
    Chairman & Chief Executive Officer
  • Rob Douglas
    President & Chief Operating Officer
  • Brett A. SandercockBrett A. Sandercock
    Chief Financial Officer
  • Carlos M. Nunez
    Chief Medical Officer
  • Urvashi Tyagi
    Chief Technology Officer













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year price objectives for ResMed's shares. Their RMD share price forecasts range from $245.00 to $280.00. On average, they predict the company's stock price to reach $263.17 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 at the beginning of 2023. Since then, RMD shares have increased by 7.8% and is now trading at $224.45.
View the best growth stocks for 2023 here
.

Are investors shorting ResMed?

ResMed saw a decrease in short interest in January. As of January 15th, there was short interest totaling 850,000 shares, a decrease of 15.8% from the December 31st total of 1,010,000 shares. Based on an average daily trading volume, of 584,000 shares, the short-interest ratio is presently 1.5 days. Approximately 0.6% of the shares of the company are sold short.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, January, 26th. The medical equipment provider reported $1.66 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.04. The medical equipment provider earned $1.03 billion during the quarter, compared to the consensus estimate of $996.22 million. ResMed had a trailing twelve-month return on equity of 25.46% and a net margin of 21.51%. The firm's quarterly revenue was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.47 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, January 26th. Stockholders of record on Thursday, February 9th will be paid a dividend of $0.44 per share on Thursday, March 16th. This represents a $1.76 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend is Wednesday, February 8th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.78%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by many different institutional and retail investors. Top institutional investors include WCM Investment Management LLC (2.61%), Ownership Capital B.V. (0.96%), Congress Asset Management Co. MA (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Welch & Forbes LLC (0.21%) and Ardevora Asset Management LLP (0.15%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $224.45.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $32.97 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.51 on an earnings per share basis.

How many employees does ResMed have?

The company employs 8,160 workers across the globe.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 2/8/2023 by MarketBeat.com Staff